Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company focused on targeting cancerCancerCancer develops when cells in the body begin to grow out of control. Normal cells grow, divide, and die. Instead of dying, cancer cells continue to grow and form new abnormal cells. Cancer cells often travel to other body parts where they grow and replace normal tissue. This spreading process is called metastasis. When cancer spreads or metastasizes, it is still named after the part of the body where it started. For example, if prostate cancer spreads to the bones, it is still prostate cancer, not bone cancer.Close and transforming lives through the discovery, development, commercialization, and manufacturing of novel therapeutics that may significantly improve cancer treatment options for patients. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI)ACTIVE CELLULAR IMMUNOTHERAPY (ACI)A therapeutic platform that uses a patient’s own cells to stimulate an immune response against cancer.Close product candidates designed to stimulate an immune response. Dendreon is headquartered in Seattle and has manufacturing facilities in New Jersey, Georgia, and California.